Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Combination of Anticholinergic and Glutamatergic Effects in Treatment-resistant Major Depressive Disorder. A Pilot Study


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT01613820

Organisation Name: Massachusetts General Hospital

Overal Status: Withdrawn

Start Date: September 2015

Last Update: February 19, 2018

Lead Sponsor: Massachusetts General Hospital

Brief Summary: Ketamine infusions resulted in an acute reduction in global depression scores and in severity of suicidal ideation. Scopolamine infusions produced also a significant improvement in depression that was sustained over time.

We therefore plan to investigate the feasibility and efficacy of open-label repeated intravenous administration of ketamine and scopolamine combined in this population of severely depressed, treatment-resistant patients. The results from this study could lead to the development of new strategies for the treatment of patients with TRD.

Conditions:
  • Major Depressive Disorder


Total execution time in seconds: 0.51423192024231